Abstract
The Hsp90 chaperones play a key role in regulating the physiology of cells exposed to environmental stress and in maintaining the malignant phenotype in tumor cells. Agents that interfere with the function of the chaperone may thus be beneficial in the treatment of cancers. The ansamycins (geldanamycin and herbimycin) and the unrelated natural product radicicol were found to bind to the N-terminal pocket of Hsp90 and inhibit its function. However, translation of these compounds to the clinic was impeded by stability and hepatoxicity issues. 17AAG, a derivative of geldanamycin, was found to be less hepatotoxic and is currently undergoing Phase I clinical trial. Unfortunately, 17AAG is insoluble, difficult to formulate and it is not yet clear if therapeutically effective doses can be administered without escalating non-Hsp90 associated toxicities. Additionally, for reasons not yet completely understood, a subset of tumor cells are insensitive to the action of the drug. The development of novel agents that lack the drawbacks of the natural products is thus necessary. Here we present an overview of such efforts with focus on a new class of purine-scaffold Hsp90 inhibitors developed by rational design.
Keywords: Purine-Scaffold, Hsp90, phenotype, geldanamycin, herbimycin
Current Cancer Drug Targets
Title: Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90
Volume: 3 Issue: 5
Author(s): Gabriela Chiosis, Brian Lucas, Henri Huezo, David Solit, Andrea Basso and Neal Rosen
Affiliation:
Keywords: Purine-Scaffold, Hsp90, phenotype, geldanamycin, herbimycin
Abstract: The Hsp90 chaperones play a key role in regulating the physiology of cells exposed to environmental stress and in maintaining the malignant phenotype in tumor cells. Agents that interfere with the function of the chaperone may thus be beneficial in the treatment of cancers. The ansamycins (geldanamycin and herbimycin) and the unrelated natural product radicicol were found to bind to the N-terminal pocket of Hsp90 and inhibit its function. However, translation of these compounds to the clinic was impeded by stability and hepatoxicity issues. 17AAG, a derivative of geldanamycin, was found to be less hepatotoxic and is currently undergoing Phase I clinical trial. Unfortunately, 17AAG is insoluble, difficult to formulate and it is not yet clear if therapeutically effective doses can be administered without escalating non-Hsp90 associated toxicities. Additionally, for reasons not yet completely understood, a subset of tumor cells are insensitive to the action of the drug. The development of novel agents that lack the drawbacks of the natural products is thus necessary. Here we present an overview of such efforts with focus on a new class of purine-scaffold Hsp90 inhibitors developed by rational design.
Export Options
About this article
Cite this article as:
Chiosis Gabriela, Lucas Brian, Huezo Henri, Solit David, Basso Andrea and Rosen Neal, Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90, Current Cancer Drug Targets 2003; 3 (5) . https://dx.doi.org/10.2174/1568009033481778
DOI https://dx.doi.org/10.2174/1568009033481778 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
OMICS-Derived Targets for Inflammatory Gut Disorders: Opportunities for the Development of Nutrition Related Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell Apoptosis
Recent Patents on Anti-Cancer Drug Discovery Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets ELISA-based Protein Arrays: Multiplexed Sandwich Immunoassays
Current Proteomics Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Design, Synthesis and In Vitro Anticancer Activity of a New Class of Bifunctional DNA Intercalators
Letters in Drug Design & Discovery Transport of Bupropion and its Metabolites by the Model CHO and HEK293 Cell Lines
Drug Metabolism Letters An Innovative Approach to Immobilize Lipase onto Natural Fiber and its Application for the Synthesis of 2-Octyl Ferulate in an Organic Medium
Current Biotechnology Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology New Insights in the Gene Electrotransfer Process: Evidence for the Involvement of the Plasmid DNA Topology
Current Gene Therapy HIV-1 Matrix Protein p17 and its Receptors
Current Drug Targets Metformin Protects the Brain Against the Oxidative Imbalance Promoted by Type 2 Diabetes
Medicinal Chemistry A3 Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin
Current Medicinal Chemistry Fullerenes for Cancer Diagnosis and Therapy: Preparation, Biological and Clinical Perspectives
Current Drug Metabolism The Impact of Crystallographic Data for the Development of Machine Learning Models to Predict Protein-Ligand Binding Affinity
Current Medicinal Chemistry Investigation of the pH Dependent Cytotoxicity of Paclitaxel Conjugated Gold Nanoparticles
Pharmaceutical Nanotechnology Bioavailability Enhancement Strategies: Basics, Formulation Approaches and Regulatory Considerations
Current Drug Delivery In situ Generation of Efficient Palladium N-heterocyclic Carbene Catalysts Using Benzimidazolium Salts for the Suzuki-Miyaura Cross-coupling Reaction
Current Organic Synthesis